Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results
Initial Data from Friedreich Ataxia Phase 1 Trial of DT-216 Expected in the Fourth Quarter of 2022 Strong Financial Position with $359.4 Million in Cash and Securities to Support Multi-Year... | August 8, 2022
United States Chelcie Lister Design Therapeutics Inc Exchange Commission Strategic Communications Association For Research
Source: marketscreener.com